Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.44 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.30 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826352 | 0.87 | POLRMT (0.36) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL25827054 | 0.86 | POLRMT (0.36) | POLRMTP2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL23278555 | 0.82 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL26003192 | 0.82 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492745 | 0.82 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492746 | 0.82 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL10120881 | 0.82 | POLRMT (0.51) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL25826842 | 0.81 | TMPRSS2 (0.42) | POLRMTTMPRSS2 | |
| SCHEMBL26327396 | 0.81 | POLRMT (0.49) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 | |
| SCHEMBL17719238 | 0.80 | POLRMT (0.48) | POLRMTTMPRSS2P2RX1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | POLRMT 139/4885TMPRSS2 145/4885P2RX1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.